CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study
Se Joon Woo, Ga Eun Cho, Joon Hee Cho
Korean J Ophthalmol. 2019;33(2):150-166.   Published online April 8, 2019
DOI: https://doi.org/10.3341/kjo.2018.0081

Excel Download

Short-term Efficacy and Safety of Ranibizumab for Neovascular Age-related Macular Degeneration in the Real World: A Post-marketing Surveillance Study
Korean Journal of Ophthalmology. 2019;33(2):150   Crossref logo
Link1 Link2 Link3

Real-world effectiveness, treatment pattern, and safety of ranibizumab in Korean patients with neovascular age-related macular degeneration: Subgroup analyses from the LUMINOUS study
. 2020;   Crossref logo
Link1 Link2

Real-World Effectiveness, Treatment Pattern, and Safety of Ranibizumab in Korean Patients with Neovascular Age-Related Macular Degeneration: Subgroup Analyses from the LUMINOUS Study
Clinical Ophthalmology. 2021;Volume 15:1995-2011   Crossref logo
Link1 Link2

Ranibizumab in patients with neovascular age-related macular degeneration: results from the real-world LUMINOUS study
Acta Ophthalmologica. 2017;95:   Crossref logo
Link1 Link2

Long-term efficacy and safety of ranibizumab administered pro re nata in Japanese patients with neovascular age-related macular degeneration in the EXTEND-I study
Acta Ophthalmologica. 2011;89(3):208-217   Crossref logo
Link1 Link2

Long-term Safety of Ranibizumab in Neovascular Age-related Macular Degeneration
Ophthalmology. 2013;120(9):e68-e69   Crossref logo
Link1 Link2

Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study)
Eye. 2021;36(5):1106-1107   Crossref logo
Link1 Link2 Link3

Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study
Clinical Ophthalmology. 2013;1849   Crossref logo
Link1

<p>Long-Term Ranibizumab Treatment in Neovascular Age-Related Macular Degeneration: A Belgian Subanalysis from the Global Real-World LUMINOUSTM Study</p>
Clinical Ophthalmology. 2020;Volume 14:1473-1481   Crossref logo
Link1 Link2

Ranibizumab: the evidence of its therapeutic value in neovascular age-related macular degeneration
Core Evidence. 2007;0   Crossref logo
Link1